Skip to main content

What the FDA labels say about taking them together

Simvastatin and ticagrelor

Ticagrelor's FDA label of May 7, 2026 names simvastatin in its drug interactions section; the simvastatin label PlainMeds reads does not name ticagrelor. The ticagrelor label: “Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects.”

Check it at the source: the simvastatin FDA label on DailyMed (effective March 28, 2025, Organon LLC); the ticagrelor FDA label on DailyMed (effective May 7, 2026, AstraZeneca Pharmaceuticals LP).

What does the simvastatin label say about ticagrelor?

Simvastatin's label (effective March 28, 2025) does not name ticagrelor in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (ZOCOR), Organon LLC, effective March 28, 2025 (SPL set 8f55d5de-5a4f-4a39-8c84-c53976dd6af9), via openFDA; the full label on DailyMed

What does the ticagrelor label say about simvastatin?

Ticagrelor label, drug interactions

Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects.

Source: FDA drug label (BRILINTA), AstraZeneca Pharmaceuticals LP, effective May 7, 2026 (SPL set f7b3f443-e83d-4bf2-0e96-023448fed9a8), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

27Simvastatin generic labelers
28Ticagrelor generic labelers
SimvastatinTicagrelor
Labeled forHeart attack and coronary artery disease, High cholesterol, High triglyceridesHeart attack and coronary artery disease, Stroke prevention
Boxed warningNoYes
Pharmacy cost (NADAC)$0.0321 per tablet 20 mg tablet$0.253 per tablet 90 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?